RG-BCMA

N/A

Report date: 2024/07/31 15:37:56

Base Information

Drug NameRG-BCMA
Drug Alias NameRG-BCMA
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy
Mechanisms of ActionNatural killer cell replacementsB-cell maturation protein modulators
TargetsB-cell maturation protein
Therapy Area/IndicationsBone Marrow Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesHangzhou Rongu Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHangzhou Rongu Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsBone Marrow Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A